Polymorphic oxidative metabolism of proguanil in a Nigerian population

European Journal of Clinical Pharmacology

Volumn 58, Issue 8, 2002, Pages 543-545

  Bolaji, O O ^a   Sadare, I O ^a   Babalola, C P ^a   Ogunbona, F A ^a  

^a OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

Author keywords

CYP2C19; Malaria; Nigerians; Proguanil

Indexed keywords

CYCLOGUANIL; CYTOCHROME P450 2C19; MEPHENYTOIN; PROGUANIL;

ADULT; AEROBIC METABOLISM; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; GENETIC DIFFERENCE; GENETIC POLYMORPHISM; HUMAN; MALE; MOLECULAR PROBE; NIGERIA; NORMAL HUMAN; PHENOTYPIC VARIATION; POPULATION DIFFERENTIATION; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE;

ADOLESCENT; ADULT; ANTIMALARIALS; ARYL HYDROCARBON HYDROXYLASES; CHLOROGUANIDE; FEMALE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; NIGERIA; OXIDATION-REDUCTION; POLYMORPHISM, GENETIC;

EID: 0036448521     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-002-0509-7     Document Type: Article

References (22)

1. Basci NE, Bozkurt A, Kortunay S, Isimer A, Sayal A, Kayadlp SO (1996) Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population. Br J Clin Pharmacol 42:771-773
2. Birkett DJ, Rees D, Andersson T, Gonzalez FJ, Miners JO, Veronese ME (1994) In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isofoms as well as by S-mephenytoin hydroxylases. Br J Clin Pharmacol 37:413-420
3. Brosen K, Skjelbo E, Flachs H (1993) Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 36:105-108
4. Edstein MD, Shanks GD, Teja-Isavadharm P, Reickmann KH, Webster HK (1994) Oxidative activation of proguanil and dapsone acetylation in Thai soldiers. Br J Clin Pharmacol 37:67-70
5. Hagg S, Spigset O, Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51:169-173
6. Helsby NA, Ward SA, Howells RE, Breckenridge AM (1990a) In vitro metabolism of the biguanide antimalarials in human liver microsomes; evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme. Br J Clin Pharmacol 30:287-291
7. Helsby NA, Ward SA, Edwards G, Howells RE, Breckenridge AM (1990b) The pharmacokinetics and activation of proguanil in man: Consequences of variation in drug metabolism. Br J Clin Pharmacol 30:593-598
8. Herrlin K, Massele AY, Rimoy G, Alm C, Rais M, Ericsson O, Bertilsson L, Gustafsson LL (2000) Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype. Clin Pharmacol Ther 68:189-198
9. Iyun AO, Tucker GT, Woods HF, Lennard MS (1990) The 4-hydroxylation of S-mephenytoin in Nigerians: A population study. Br J Clin Pharmacol 30:312P
10. Llerena A, Cobaleda J, Martinez C, Benitez J (1996) Interethnic differences in drug metabolism: Influence of genetic and environmental factors on debrisoquine hydroxylation phenotype. Eur J Drug Metab Pharmacokinet 21:129-138
11. Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M (1995) Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 57:656-661
12. Meibohm B, Beierle I, Derendorf H (2002) How important are gender differences in pharmacokinetics? Clin Pharmacokinet 41:329-342
13. Onyeji CO, Ogunbona FA, Dixon PAF (1989) Excretion of proguanil in human saliva. J Pharm Pharmacol 41:872-873
14. Partovian C, Jacqz-Aigrain E, Keundjian A, Jaillon P, Funck-Brentano C (1995) Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans. Clin Pharmacol Ther 58:257-263
15. Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelman-Sundberg (1996) S-Mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 6:521-526
16. Roh H, Dahl M, Johansson I, Ingelman-Sundberg M, Cha Y, Bertilsson L (1996) Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 6:441-447
17. Setiabudy R, Kusaka M, Chiba K, Darmansjah I, Ishizaki T (1995) Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'hydroxylation recruited from an Indonesian population. Br J Clin Pharmacol 39:297-303
18. Skjelbo E, Mutabingwa TK, Bygbjerg I, Nulsen KK Gram LF, Brosen K (1996) Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther 59:304-311
19. Wanwimolruk S, Thou MR, Woods DJ (1995) Evidence for the polymorphic oxidation of proguanil in a Khmer (Cambodian) population. Br J Clin Pharmacol 40:166-169
20. Ward SA, Watkins WM, Mberu E, Saunders JE, Koech DK, Gilles HM, Howells RE, Breckenridge AM (1989) Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol 27:781-787
21. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LD, Breckenridge AM (1991) The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - A panel study. Br J Clin Pharmacol 31:689-692
22. Wright JD, Helsby NA, Ward SA (1995) The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides. Br J Clin Pharmacol 39:441-444